Breakthrough for Deep Tech in Sri Lanka: JENDO Secures New Investment Milestone

A Major Milestone for Sri Lankan Deep Tech

Jendo Innovations, a Sri Lankan biomedical startup, has achieved a major milestone by successfully closing a new investment round, reinforcing its position as a rising force in global health technology. Valued at several million dollars, the company has developed an advanced AI-powered medical device capable of detecting early-stage heart disease in just 15 minutes—offering a faster, non-invasive alternative to traditional diagnostic methods.

From University Project to Global Innovation

Founded and led by Keerthi Kodithuwakku, Jendo has evolved from a university project into a globally recognized innovation. The device leverages machine learning and cloud-based analysis to identify endothelial dysfunction, the earliest detectable stage of cardiovascular disease, enabling preventive care long before symptoms appear.

Expanding to International Markets

The recent investment, largely backed by US investors, marks a critical step in Jendo's expansion strategy, particularly as it prepares to enter the US market with regulatory processes such as FDA approval already in progress. The company is also gearing up for its upcoming Series A funding round, aimed at accelerating international growth and scaling its impact.

Global Recognition and Pathways to Success

Jendo's journey has been supported by globally recognized programs such as the Stanford Seeds Accelerator and the John Keells X (JKX) Accelerator, helping the team navigate complex global markets. Its credibility is further strengthened by patents secured across multiple countries and recognition at leading international platforms, including the World Intellectual Property Organization.

From Reactive to Proactive Healthcare

By combining engineering excellence with medical expertise, Jendo is contributing to a shift from reactive healthcare to proactive prevention. Its scalable technology has the potential to expand access to early cardiovascular screening across both urban and underserved regions, positioning Sri Lanka as an emerging hub for deep-tech and biomedical innovation.